CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of Allogeneic Ex Vivo Expanded Gamma Delta (γδ) T Cells in Combination With Dinutuximab, Temozolomide, Irinotecan, and Zoledronate in Children With Refractory/ Relapsed, or Progressive Neuroblastoma or Refractory/ Relapsed Osteosarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05400603
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:44.256420+00:00
Published At: 2025-12-26T00:00:00+00:00
Record Updated At: 2025-12-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Neuroblastoma", "Refractory Neuroblastoma", "Relapsed Neuroblastoma", "Relapsed Osteosarcoma", "Refractory Osteosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-26"
protocolSection.identificationModule.nctId: "NCT05400603"
protocolSection.identificationModule.officialTitle: "A Phase I Study of Allogeneic Ex Vivo Expanded Gamma Delta (\u03b3\u03b4) T Cells in Combination With Dinutuximab, Temozolomide, Irinotecan, and Zoledronate in Children With Refractory/ Relapsed, or Progressive Neuroblastoma or Refractory/ Relapsed Osteosarcoma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.